| Primary |
| Enuresis |
26.0% |
| Product Used For Unknown Indication |
19.2% |
| Hypopituitarism |
11.0% |
| Diabetes Insipidus |
9.6% |
| Hormone Replacement Therapy |
5.5% |
| Nocturia |
4.1% |
| Asthma |
2.7% |
| Depression |
2.7% |
| Hypertonic Bladder |
2.7% |
| Pituitary Tumour |
2.7% |
| Back Pain |
1.4% |
| Coagulopathy |
1.4% |
| Constipation |
1.4% |
| Diabetes Mellitus Insulin-dependent |
1.4% |
| Diarrhoea |
1.4% |
| Gastritis |
1.4% |
| Hypertension |
1.4% |
| Malaise |
1.4% |
| Mood Altered |
1.4% |
| Panhypopituitarism |
1.4% |
|
| Drug Ineffective |
21.1% |
| Hyponatraemia |
10.5% |
| Prinzmetal Angina |
7.9% |
| Intestinal Ischaemia |
5.3% |
| Overdose |
5.3% |
| Product Tampering |
5.3% |
| Rash |
5.3% |
| Thirst |
5.3% |
| Vertigo |
5.3% |
| Angioedema |
2.6% |
| Blood Sodium Decreased |
2.6% |
| Diarrhoea |
2.6% |
| Dysuria |
2.6% |
| Fear |
2.6% |
| Histiocytosis |
2.6% |
| Hypertension |
2.6% |
| Hypoglycaemia |
2.6% |
| Mania |
2.6% |
| Mesenteric Vein Thrombosis |
2.6% |
| Nausea |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
30.3% |
| Enuresis |
7.9% |
| Obsessive-compulsive Disorder |
7.9% |
| Drug Use For Unknown Indication |
5.3% |
| Congestive Cardiomyopathy |
3.9% |
| Convulsion |
3.9% |
| Hypertension |
3.9% |
| Ill-defined Disorder |
3.9% |
| Prophylaxis |
3.9% |
| Type 2 Diabetes Mellitus |
3.9% |
| Antibiotic Therapy |
2.6% |
| Asthma |
2.6% |
| Diabetes Insipidus |
2.6% |
| Gout |
2.6% |
| Hypertonic Bladder |
2.6% |
| Hypopituitarism |
2.6% |
| International Normalised Ratio Increased |
2.6% |
| Macular Degeneration |
2.6% |
| Strongyloidiasis |
2.6% |
| Bladder Prolapse |
1.3% |
|
| Vomiting |
14.8% |
| Haematocrit Decreased |
11.1% |
| Hyponatraemia |
7.4% |
| Muscular Weakness |
7.4% |
| Myocardial Infarction |
7.4% |
| Bladder Cancer |
3.7% |
| Blood Creatine Phosphokinase Increased |
3.7% |
| Dysgeusia |
3.7% |
| Epilepsy |
3.7% |
| Hypertension |
3.7% |
| Hypoglycaemia |
3.7% |
| Labelled Drug-drug Interaction Medication Error |
3.7% |
| Loss Of Consciousness |
3.7% |
| Prinzmetal Angina |
3.7% |
| Product Tampering |
3.7% |
| Rash |
3.7% |
| Rash Generalised |
3.7% |
| Stent Occlusion |
3.7% |
| Vasculitis |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
8.8% |
| Hypopituitarism |
8.5% |
| Growth Hormone Deficiency |
7.6% |
| Blood Antidiuretic Hormone Decreased |
6.7% |
| Primary Hypothyroidism |
6.2% |
| Blood Corticotrophin Decreased |
5.8% |
| Follicle-stimulating Hormone Deficiency |
5.6% |
| Blood Thyroid Stimulating Hormone Decreased |
5.5% |
| Adh Decreased |
5.2% |
| Blood Follicle Stimulating Hormone Decreased |
5.1% |
| Acth Decreased |
4.9% |
| Blood Luteinising Hormone Decreased |
4.8% |
| Hypogonadism |
3.9% |
| Luteinising Hormone Deficiency |
3.9% |
| Diabetes Insipidus |
3.6% |
| Drug Use For Unknown Indication |
3.5% |
| Hypothyroidism |
3.3% |
| Essential Hypertension |
2.5% |
| Ovarian Disorder |
2.4% |
| Hypertension |
2.3% |
|
| Neoplasm Recurrence |
9.6% |
| Granulocytopenia |
8.9% |
| Vomiting |
7.6% |
| Death |
7.0% |
| Craniopharyngioma |
6.4% |
| Pituitary Tumour Benign |
5.7% |
| Pneumonia |
5.1% |
| Weight Increased |
5.1% |
| Arthropathy |
4.5% |
| Gastroenteritis Viral |
4.5% |
| Leukopenia |
4.5% |
| Pain |
4.5% |
| Malaise |
3.8% |
| Priapism |
3.8% |
| Cerebrovascular Accident |
3.2% |
| Depression |
3.2% |
| Hyponatraemia |
3.2% |
| Influenza |
3.2% |
| Nervous System Disorder |
3.2% |
| White Blood Cell Count Decreased |
3.2% |
|
| Interacting |
| Analgesia |
40.0% |
| Product Used For Unknown Indication |
30.0% |
| Analgesic Therapy |
20.0% |
| Enuresis |
10.0% |
|
| Hyponatraemia |
60.0% |
| Labelled Drug-drug Interaction Medication Error |
20.0% |
| Resting Tremor |
20.0% |
|
